In the prospective CATNON trial (which compares radiotherapy with or without chemotherapy), a subgroup analysis of IDHwt astrocytoma with molecular features of glioblastoma demonstrated improved survival for tumors with MGMT promotor methylation (but surprisingly did not find evidence for beneficial effects of alkylating chemotherapy among methylated tumors) [7]. This evidence concerns the gene MGMT and astrocytoma (excluding glioblastoma).